Clifford Feldman
Psychiatry · Pasadena, CANPI 1396751533
Payments from drug & device makers
What this record shows
7 manufacturers reported payments, led by Ipsen Innovation at 41.6% of the total. Reporting peaked in 2024 at $3,531 and has fallen 96.7% since, to $117 in 2025. Among psychiatry clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 45 payments — averaging $96.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ipsen Innovation$2K
- E.r. Squibb & Sons, L.L.C.$1K
- Johnson & Johnson$825
- Neurocrine Biosciences, Inc.$177
- Neuronetics, Inc.$137
- Sunovion Pharmaceuticals Inc.$32
- plus $15 from 1 others
Across 84 payments — averaging $20,182 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$964K
- Eli Lilly$462K
- Alkermes, Inc.$76K
- E.r. Squibb & Sons, L.L.C.$53K
- Vanda Pharmaceuticals Inc.$51K
- Janssen Research & Development, LLC$41K
- plus $49K from 4 others
What the payments were for
- Travel & lodging$2,51158%
- Food & beverage$1,85042%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ipsen Innovation | 3 | $1,815 |
| E.r. Squibb & Sons, L.L.C. | 3 | $1,359 |
| Johnson & Johnson | 26 | $825 |
| Neurocrine Biosciences, Inc. | 7 | $177 |
| Neuronetics, Inc. | 2 | $137 |
| Sunovion Pharmaceuticals Inc. | 3 | $32 |
| Indivior Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$125
How this compares
$4,362 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aripiprazole | 23 | $1,288 |
| Divalproex Sodium | 27 | $624 |
| Quetiapine Fumarate | 22 | $268 |
| Divalproex Sodium ErDivalproex Sodium | 16 | $217 |
| Olanzapine | 20 | $203 |
| Haloperidol | 17 | $161 |
| Benztropine Mesylate | 20 | $147 |
| Duloxetine Hcl | 18 | $123 |
| Bupropion XlBupropion Hcl | 11 | $97 |
| Topiramate | 12 | $95 |
| Mirtazapine | 24 | $92 |
| Escitalopram Oxalate | 15 | $91 |
| Propranolol Hcl | 12 | $85 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Pasadena
- Gustavo AlvaOrange$5.8M
- John KooSan Francisco$3M
- Jason KelloggIrvine$2.7M
- Jonathan MeyerSan Diego$2.3M
- Charles Tuan-Tu NguyenIrvine$2.1M
- Manoj WaikarLos Gatos$1.9M
- Gerald MaguireSan Juan Capistraco$1.8M
- Salima BrillmanSunnyvale$1.4M
- Bibi DasStanford$1.4M
- Konstantinos TripodisBurbank$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.